Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference32 articles.
1. What is the best strategy for targeting EGF receptors in nonsmall-cell lung cancer Future O;Pirker;ncol,2015
2. Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.;Pirker;Curr Opin Oncol,2015
3. Cetuximab plus chemotherapy in patients with advanced nonsmall-cell lung cancer (FLEX): an open-label randomised phase III trial.;Pirker;Lancet,2009
4. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced nonsmall-cell lung cancer: analysis of data from the phase 3 FLEX study.;Pirker;Lancet Oncol,2012
5. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous nonsmall-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.;Thatcher;Lancet Oncol,2015
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Transcriptomic Analysis Reveals Early Alterations Associated with Intrinsic Resistance to Targeted Therapy in Lung Adenocarcinoma Cell Lines;Cancers;2024-07-08
2. Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications;Cells;2023-12-25
3. Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis;Pharmacology;2022-12-05
4. Development and Optimization of Osimertinib-loaded Biodegradable Polymeric Nanoparticles Enhance In-vitro Cytotoxicity in Mutant EGFR NSCLC Cell Models and In-vivo Tumor Reduction in H1975 Xenograft Mice Models;AAPS PharmSciTech;2022-06-08
5. Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance;Frontiers in Oncology;2022-04-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3